Consider the peculiar fate of a company that spends billions acquiring another company and then disappears from the door. On August 27, 2018, Verscend completed its purchase of Cotiviti. Verscend’s chief executive, Emad Rizk, would run the combined business. Its private equity owner, Veritas Capital, remained behind it. But the name that survived was Cotiviti. To understand the transaction, it helps to follow something less glamorous than a corporate identity: the journey of a healthcare claim.
- Find the mismatch. Verscend checked payments, population risk, and reported quality.
- Connect the work. Software came with record retrieval, review, and specialist services.
- Buy more reach. The 2018 Cotiviti deal combined complementary clinical and financial capabilities.
The buyer takes the name
A claim is a financial document describing a clinical event. That double identity creates an awkward problem. A health plan needs to know whether the payment is correct, what the patient’s conditions imply about future costs, and whether appropriate care is reaching that patient. Those questions touch the same healthcare system, but answering them requires different tools and expertise.
Verscend assembled a business around those connections. It emerged from Verisk Health, which Veritas agreed to buy for $820 million in 2016. The sale closed that June; the Verscend name arrived in August. This was an existing operating business gaining a new owner and identity. Rizk joined as CEO during the transition.
The seller had its own logic. Verisk said the divestiture would sharpen its focus on proprietary analytics in its other markets, and it would provide transitional services as the healthcare operation separated. For the buyer, independence created a more concentrated healthcare business. The same transaction could therefore serve two different strategies: a narrower portfolio for one owner and a platform to expand for another.
Two years later, the announced Cotiviti transaction carried an enterprise value of approximately $4.9 billion, including debt. Shareholders received $44.75 per share. These figures describe an acquisition, not a software subscription or Verscend’s revenue. The strategic argument was straightforward: combine datasets, analytics, customers, and specialists that approached healthcare spending from complementary directions.
One population, several questions
Take Medical Intelligence, Verscend’s performance analytics product. Powered by DxCG risk modeling, it helped organizations examine spending, utilization, and differences in practice patterns. Its August 2018 release added preconfigured charts, standard dashboards, and ways to copy and share them. An emergency-room dashboard gave customers a starting point for examining a familiar cost problem.
The detail is revealing. The improvement involved making existing intelligence easier for different people to reach. A sophisticated model has limited practical value if the person responsible for a decision cannot get a useful answer from it. Verscend’s product team was addressing that last stretch between analysis and use.
Quality Intelligence served a different job: measuring and reporting care quality, including HEDIS and Star Ratings. In February 2018, Verscend said more than 100 organizations used its quality measurement and reporting solutions. Its Quality Engine had earned NCQA measure certification for the seventeenth consecutive year. Certification concerns measure logic; it does not establish that software alone improves a patient’s health.
Payment Accuracy focused on incorrect payments and suspected fraud, waste, and abuse. Risk adjustment supported the assessment of population illness burden. Earlier in 2018, Verscend announced an agreement to acquire commercial payer products from General Dynamics Information Technology, extending its program-integrity and medical-quality capabilities.
The report arrived too late
The operational problem becomes clearer in a published Verscend case study about CareOregon. Its early quality work was seasonal and retrospective. The arrival of Five Star incentives in 2012 helped change that approach. Looking backward was not producing the quality improvements the plan wanted.
CareOregon began using Verscend’s predecessor in 2013. Quality Intelligence supported more frequent measurement. Weekly care-gap reports reached teams that could arrange outreach and interventions, including clinic coordinators and pharmacy staff. The useful change was a shorter interval between discovering a gap and doing something about it.
There is a copyable idea here: give a recurring finding an owner and a response schedule. That lesson depends on access to usable records and staff who can intervene. A report without those conditions risks becoming an unusually well-organized description of unfinished work.
The people behind the percentage
Verscend’s 2017 Healthcare Informatics listing contains a useful corrective to the usual software story. It reported a revenue mix of 65% services and 35% software. The business required considerable human work. Premera’s provider bulletin offers a concrete example: physicians could expect Verscend to contact them about medical records needed for quality measurement.
This places Verscend in an enterprise market where expertise and execution matter alongside code. Its customers included health plans and other organizations carrying financial risk. Its work connected analytics with record retrieval, abstraction, reporting, and review. The purchase decision therefore involved an operating relationship as well as a technical capability.
For a buyer, the sensible evaluation starts with a specific workflow. Ask which records enter the system, who reviews an exception, and where the result goes next. Compare the cost of implementation and specialist work alongside the software charge. That is an editorial buying test, rather than a claim about any particular contract: useful analysis needs a route into everyday decisions.
Alternatives vary by task. Optum, Zelis, and Lyric compete in payment-integrity categories; Inovalon appears in quality-reporting workflows. Verscend’s argument was breadth across adjacent payer problems. That breadth creates a buying question: can the combined capabilities fit the customer’s actual processes? A long product list does little by itself to answer it.
“The name Verscend implies growth, ascension, momentum”Emad Rizk · brand announcement, August 2016
The name changed. The work expanded.
The subsequent history belongs to Cotiviti. In May 2024, KKR joined Veritas as an equal-ownership co-sponsor. In March 2025, Cotiviti completed its acquisition of Edifecs, adding healthcare interoperability capabilities. Ric Sinclair became CEO in March 2026, while Rizk moved into a senior advisor role.
By October 2026, the successor’s announcements included unified inpatient claim review and earlier action on care gaps. The vocabulary had expanded, but the practical question remained familiar: can the right information arrive before the opportunity to act has passed? That is a useful way to judge this business. Follow what happens after the finding.